These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33704186)

  • 1. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
    Turshudzhyan A; Vredenburgh J
    Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    Jiang L; Yang P; Liu Y; Li J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
    Negrao MV; Raymond VM; Lanman RB; Robichaux JP; He J; Nilsson MB; Ng PKS; Amador BE; Roarty EB; Nagy RJ; Banks KC; Zhu VW; Ng C; Chae YK; Clarke JM; Crawford JA; Meric-Bernstam F; Ignatius Ou SH; Gandara DR; Heymach JV; Bivona TG; McCoach CE
    J Thorac Oncol; 2020 Oct; 15(10):1611-1623. PubMed ID: 32540409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].
    Deng L; Yang Y; Huang J
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
    Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
    J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
    Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encorafenib plus binimetinib in patients with
    Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
    Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
    Riudavets M; Cascetta P; Planchard D
    Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
    Rustgi N; Maria A; Toumbacaris N; Zhao H; Kargus K; Bryant M; Waksmundzki A; Aricescu I; Lefkowitz RA; Li BT; Chou J; Capanu M; de Stanchina E; Misale S; Shia J; Yaeger R
    Oncologist; 2024 Jan; 29(1):15-24. PubMed ID: 37616543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
    Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM
    Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
    Wu H; Feng J; Lu S; Huang J
    Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
    Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;
    Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in anti-BRAF therapies for lung cancer.
    Roviello G; D'Angelo A; Sirico M; Pittacolo M; Conter FU; Sobhani N
    Invest New Drugs; 2021 Jun; 39(3):879-890. PubMed ID: 33474634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.
    Huang Z; Wang Y; Li B; Xu Y; Huang G; Song Y; Li J; Song L; Wang J; Wang R; Liang N; Li S
    Thorac Cancer; 2024 Aug; 15(24):1825-1828. PubMed ID: 39020500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
    Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C
    Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.